-
Mashup Score: 44Moving Forward Liquid Biopsy in Early Liver Cancer Detection - 8 month(s) ago
Summary:. Early cancer detection is an attractive and promising application for liquid biopsy that might revolutionize cancer screenings. In this issue of Cancer Discovery, Foda and colleagues expand the potential utility of a machine learning fragmentome-based model, called DELFI, for detecting liver cancer in high-risk patients.See related article by Foda et al., p. 616 (5).
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 42Moving Forward Liquid Biopsy in Early Liver Cancer Detection - 8 month(s) ago
Summary:. Early cancer detection is an attractive and promising application for liquid biopsy that might revolutionize cancer screenings. In this issue of Cancer Discovery, Foda and colleagues expand the potential utility of a machine learning fragmentome-based model, called DELFI, for detecting liver cancer in high-risk patients.See related article by Foda et al., p. 616 (5).
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
And our editorial to this great paper ! @Al3ssandroRusso @CD_AACR @ElizSMcKenna @isliquidbiopsy https://t.co/smCLOG0YVH https://t.co/fu9jfttWVl https://t.co/iqTC3lmiRY
-
-
Mashup Score: 51
Since 2012 when immune checkpoint inhibitors reported the first signals of activity in advanced non–small cell lung cancer (NSCLC),1,2 immunotherapy has progressively revolutionized the therapeutic landscape of this disease moving from pretreated metastatic disease to earlier stages, including the…
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
🚨📣Today our editorial with @Al3ssandroRusso in @JAMAOnc The Chemoimmunotherapy Revolution in Resectable NSCLC—The Times They Are A-Changin’ on the terrific paper of @DoctorJSpicer and team! @TischCancer @IcahnMountSinai https://t.co/YXgBaOv79V
-
-
Mashup Score: 28
Background Immune-checkpoint inhibitors (ICIs) have showed unprecedent efficacy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). However, not all patients manifest clinical benefit due to the lack of reliable predictive biomarkers. We showed preliminary data on the predictive role of the combination of radiomics and plasma extracellular vesicle (EV) PD-L1 to predict durable response to ICIs. Main body Here, we validated this model in a prospective cohort of patients receiving ICIs plus chemotherapy and compared it with patients undergoing chemotherapy alone. This multiparametric model showed high sensitivity and specificity at identifying non-responders to ICIs and outperformed tissue PD-L1, being directly correlated with tumor change. Short conclusion These findings indicate that the combination of radiomics and EV PD-L1 dynamics is a minimally invasive and promising biomarker for the stratification of patients to receive ICIs.
Source: jeccr.biomedcentral.comCategories: General Medicine News, Hem/OncsTweet-
Validation of multiomic model of plasma extracellular vesicle PD-L1& radiomics for prediction response to IO in NSCLC @ddemiguelperez @ogarrieta @ANaingMD @Al3ssandroRusso @fred_hirsch @AndresFCardonaZ https://t.co/iaAFkeKsSg
-
-
Mashup Score: 4Role of HLA in Lung Cancer Highlighted in New Study - 9 month(s) ago
Heterozygosity in human leukocyte antigen (HLA) reduces risk of developing lung cancer, especially in smokers, according to a new study.
Source: www.insideprecisionmedicine.comCategories: General Medicine News, Hem/OncsTweet-
RT @TischCancer: Role of HLA in Lung Cancer Highlighted in New Study https://t.co/TRnzLn2por via @clinicalomics @diegochowell @rsamstein @…
-
-
Mashup Score: 46ISLB 2024 - Save The Date! - ISLB 2024 - 9 month(s) ago
SEE YOU AT ISLB 2024 Denver, Colorado, USA | November 23-25, 2024 Stay up to date with Congress News Subscribe to Our Newsletter
Source: 2024.islb.infoCategories: General Medicine News, Hem/OncsTweet-
🚨🔔ISLB 2024 - Save The Date! 23-25 November 2024 in Denver Colorado!. 🏔️🌆Subscribe for the newsletter and prepare your abstracts!! @MJOSESERRANO19 @UmbertoMalapel1 @drgandara @MCristofanill @ElJanLe https://t.co/41IBMVqMSI
-
-
Mashup Score: 72Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment - 9 month(s) ago
PURPOSE Studies have investigated the early use of liquid biopsy (LBx) during the diagnostic workup of patients presenting with clinical evidence of advanced lung cancer, but real-world adoption and impact has not been characterized. The aim of this study was to determine whether the use of LBx before diagnosis (Dx; LBx-Dx) enables timely comprehensive genomic profiling (CGP) and shortens time until treatment initiation for advanced non–small-cell lung cancer (aNSCLC). MATERIALS AND METHODS This study used the Flatiron Health-Foundation Medicine electronic health record-derived deidentified clinicogenomic database of patients with aNSCLC from approximately 280 US cancer clinics. RESULTS Of 1,076 patients with LBx CGP ordered within 30 days prediagnosis/postdiagnosis, we focused on 56 (5.2%) patients who ordered LBx before diagnosis date (median 8 days between order and diagnosis, range, 1-28). Compared with 1,020 patients who ordered LBx after diagnosis (Dx-LBx), LBx-Dx patients had si
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment @JCOPO_ASCO @isliquidbiopsy @Al3ssandroRusso @Marzia_DelRe @geoff_oxnard @TischCancer @ASCO https://t.co/jMzZ4zIeB2
-
-
Mashup Score: 39ISLB 2024 - Save The Date! - ISLB 2024 - 9 month(s) ago
SEE YOU AT ISLB 2024 Denver, Colorado, USA | November 23-25, 2024 Stay up to date with Congress News Subscribe to Our Newsletter
Source: 2024.islb.infoCategories: General Medicine News, Hem/OncsTweet-
🚨🔔ISLB 2024 - Save The Date! 23-25 November 2024 in Denver Colorado!. 🏔️🌆Subscribe for the newsletter and prepare your abstracts!! @MJOSESERRANO19 @UmbertoMalapel1 @drgandara @MCristofanill @ElJanLe https://t.co/41IBMVqMSI
-
-
Mashup Score: 71Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma. - 1 year(s) ago
Pleural mesothelioma (PM) is an aggressive tumor still considered incurable, in part due to the lack of predictive biomarkers. Little is known about the clinical implications of molecular alterations in resectable PM tissues and blood. Here, we characterized genetic alterations to identify prognostic and predictive biomarkers in patients with resected PM.
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet-
📣Our paper “Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma” is online now! @ElsevierConnect @ddemiguelperez @Al3ssandroRusso @TischCancer @IcahnMountSinai @MSHSThoracicOnc @curemeso https://t.co/GdDWBGSenk
-
-
Mashup Score: 41ISLB 2023 - ISLB 2023 - 1 year(s) ago
Welcome to the5th Annual Congress of Liquid Biopsy Christian Rolfo ISLB President It is my greatest pleasure to welcome you all to the 5th Congress of Liquid Biopsy: “Opportunities and Challenges of Liquid Biopsy” (ISLB23) in our beautiful city of Madrid, Spain. Liquid biopsy is a fascinating and exponentially growing field that has a tremendous … ISLB 2023 Read More »
Source: 2023.islb.infoCategories: General Medicine News, Hem/OncsTweet-
Nice collection of #liquidbiopsy papers of @CD_AACR If you’re interested in the field we wait for you at #ISLB23 in Madrid November 19-21 🇪🇸 More info https://t.co/vRM2LCzvcJ @UmbertoMalapel1 @MCristofanill @MJOSESERRANO19 @drgandara @ElJanLe @isliquidbiopsy https://t.co/3EwJf6P9rI https://t.co/8PqE3B9qqJ
-
And our editorial to this great paper ! @Al3ssandroRusso @CD_AACR @ElizSMcKenna @isliquidbiopsy https://t.co/smCLOG0YVH https://t.co/fu9jfttWVl https://t.co/iqTC3lmiRY